The Opioid Epidemic: Regulation, Responsibility, and Remedies by unknown
 [317] 
TENNESSEE JOURNAL 
OF LAW AND POLICY 
 
 
VOLUME 13 SUMMER 2018 SPECIAL EDITION 
 
 
THE OPIOID EPIDEMIC 
REGULATION, RESPONSIBILITY, AND REMEDIES 
 
Tricia Herzfeld 
Gerald Stranch 
Zack Buck 
 
MR. GROVES: My name is Alan Groves. I served 
as the Editor in Chief of the Tennessee Journal of Law 
and Policy from February 2017 until just a few weeks 
ago. My successor Editor in Chief will be moderating our 
second panel this afternoon. Our first panel discussion 
today is going to focus on some of the questions you all 
were asking at the end of the last session about 
regulation, responsibilities and remedies. So, our first 
two panelists to my immediate right come from the firm 
of Branstetter, Stranch and Jennings located in 
Nashville, Tennessee. In the past year, their firm has 
filed three different lawsuits in Tennessee against 
several opioid manufacturers. Tricia Herzfeld is a 2001 
graduate of George Washington University Law School 
and is now a partner at Branstetter, Stranch and 
Jennings. Ms. Herzfeld has previously served as Legal 
Director of the American Civil Liberties Union of 
Tennessee where she successfully litigated dozens of 
high-profile civil rights cases in state and federal courts. 
She has also served as a public defender in Miami where 
she conducted over 80criminal trials. In 2012, she was 
selected as one of the nation’s Super Lawyers, and among 
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those with that honor, she attained Rising Star status in 
2013.  
Her colleague, Gerald Stranch, received his law 
degree from Vanderbilt University. He is now the 
managing member of Branstetter, Stranch and Jennings 
and chairs the firm’s complex litigation team. He 
oversees the firm’s securities, class actions, antitrust, 
shareholder derivative, mass tort and consumer class 
cases. Mr. Stranch also served as an adjunct professor at 
Vanderbilt University School of Law. He was named the 
top 40 under 40 from the National Trial Lawyers 
Association and was named the Mid-South Rising Star by 
Super Lawyers.  
And finally, Professor Zack Buck at the end of the 
table, teaches a variety of health law classes at the 
University of Tennessee College of Law, including a 
bioethics and public health seminar, torts, health care 
finance and organization, health care regulation and 
quality, and health care fraud and abuse. His scholarship 
examines governmental enforcement of laws affecting 
health and health care in the United States. Before 
joining UT, Professor Buck taught at Mercer University 
School of Law, Seton Hall University School of Law and 
the University Pennsylvania School of Law. He also 
practiced complex commercial litigation at Sidley Austin 
in Chicago.  
So, with this distinguished panel now introduced, 
let’s just jump right into our first question, and we are 
going to start off where the last panel ended talking about 
remedies and particularly the search for a cause of action 
in some of these lawsuits that have been filed.  
So, Ms. Herzfeld, I’ll throw this first question to 
you. Can you talk to us a little bit about the suits that 
your firm has filed and particularly why you chose to 
bring those causes of action that you did, the statutory 
and the common law public nuisance claims and then 
also a cause of action under Tennessee’s Drug Dealer 
Liability Act. 
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MS. HERZFELD: Sure. Thanks very much for 
having us. We appreciate the opportunity to talk about 
our lawsuits. Lawyers always like to talk about their 
lawsuits, so we can answer any questions you all have, 
and we happily do so. Our lawsuit that we brought− we 
have actually brought three different lawsuits 
throughout Tennessee. They have been filed in the 
Tennessee state courts. So that means our lawsuits are a 
little bit different than the vast majority of them across 
the country. Those have been filed primarily in federal 
court or have been moved to federal court. So, we made a 
very, very rational, I think, and determined decision that 
we wanted to keep our cases in state court, and there 
were some reasons for that. We don’t think that a federal 
judge, with all due respect to the federal judiciary in 
Cleveland, Tennessee, where the multi−district litigation 
is, is going to have the same understanding of the real 
day-to-day impact of the opioid crisis. So, we really made 
a point to file our cases in Tennessee.  
So, the first case that we filed is in Sullivan 
County, Tennessee, so up in the very, very top corner in 
the Appalachian region where it is really ground zero to 
the opioid epidemic here in Tennessee. They have the 
number one statistics for births of children that are born 
dependent on opioids, and so those children are classified 
as having neonatal abstinence syndrome, and that was 
the primary reason that we decided to file that first case 
there. Our cases are a little bit different than many of the 
others, because ours has primarily been filed by District 
Attorney Generals, and I think you are going to hear from 
one of our clients a little bit later today. We did that 
because we have a somewhat unique− I say unique, sort 
of− statute in Tennessee called the Drug Dealer Liability 
Act. Now, the Drug Dealer Liability Act initially was put 
together by an organization called ALEC. Has anybody 
heard of ALEC? American Legislative and Exchange 
Council.  
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So, they put together somewhat conservative 
proposed legislation and kind of pushed that legislation 
out throughout the country. I think it was 23 states ended 
up passing various versions of the Drug Dealer Liability 
Act back in the day, and Tennessee was one of them. 
Now, initially the Drug Dealer Liability Act was 
supposed to− I think the thought process at that point 
was, there was a crack cocaine epidemic, and the idea was 
to be able to go after the higher−level drug dealer chain, 
not just the person you’re buying from or the person at 
the drug house, but kind of going up until you get to the 
suppliers and the producers, further and further. So, we 
took that law and decided, well, it kind of seems like the 
same thing for opioids; right? You have the street-level 
dealers. You have the people that they are getting them 
from. You have the pill mill doctors who are supplying 
them, which is often without a legitimate prescription; 
that’s mostly how that happens. They get them from 
various pharmacies, who get them from distributors, who 
ultimately get them from producers. And why is that any 
different than a drug cartel? So that’s why we decided to 
file under the Drug Dealer Liability Act, because, 
truthfully, we think the opioid epidemic and the way that 
it’s impacted Tennesseans and most of the state, it really 
is illegal drug activity; right? That’s really what we’re 
talking about. It may have the veneer of being legal, 
because there are legal uses for opioids, but the legal uses 
of opioids are not what is causing this epidemic and 
causing so many people to die. It’s the illegal uses.  
So, we’re really trying to tackle it from that way. 
Now, the Drug Dealer Liability Act has a lot of benefits 
to it. One of them that we really like is, there’s not that 
level of causation. So, the principles of this law are more 
actually rooted in antitrust, so it’s market participation. 
So, all we have to prove− all we have to prove− is that 
someone or a corporation knowingly participated in the 
illegal drug market, and as you have heard earlier, with 
those numbers, how could you not have known; right? I 
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mean, the diversion is clear, the news stories are clear; 
we simply have to prove that they knowingly participated 
in this illegal drug market. Now, a lot of other causes of 
action shave been filed, a bunch of other different 
lawsuits across the country. They are more of a 
traditional negligent standard, where you would have to 
prove in this context that this individual got this pill from 
this person, there was a duty, there was a breach, and 
you’re going to have to work your way all the up pill by 
pill all the way through. That’s not required under the 
Drug Dealer Liability Act. So that’s why we chose that 
cause of action. The other one that we filed is, we filed 
under common law and statutory nuisance, and you will 
see nuisance showing up in a lot of the lawsuits 
throughout the country. Specifically, for us, our District 
Attorneys typically file nuisance lawsuits. They are the 
ones who file those. They shut down houses of 
prostitution. They shut down crack houses. They do this 
stuff all the time. So, it meshed very well with an 
additional cause that is typically within their purview 
infighting crime. So, the purpose of our lawsuit is to focus 
less kind of on consumer protection, more to really focus 
on the fact that these drugs are now being used illegally 
and everybody knows it. 
 
MR. GROVES: Mr. Stranch, I’ll throw the next 
question to you. Ms. Herzfeld just talked about the state 
law claims that your firm has brought, the Tennessee 
Drug Dealer Liability Act and then the common law and 
statutory public nuisance claims. Some attorneys for the 
opioid manufacturers have argued that federal 
regulations actually preempt any state law claims. So, 
what is your response to that argument? 
 
MR. STRANCH: Those defense lawyers are 
saying anything and everything they can to try to shut 
this litigation down. They are absolutely shameless. They 
are even attacking whether cities and counties have the 
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authority to bring the lawsuit or to hire outside counsel 
to do it. Their entire strategy right now is delay, delay, 
delay as long as possible. I don’t think the federal 
regulations preempt anything in our litigation in 
particular, because we have specific state statutory 
claims that don’t talk, reference or have anything to do 
with federal regulations. One thing that’s clear is, this is 
not a complete preemption area like an ERISA where any 
claim at all would be preempted− field preemption is 
what it’s called. They have not really raised federal 
preemption in our case in the motion to dismiss that we 
already argued. They did throw in the rest of the kitchen 
sink, though. Some of the other cases that are out there 
might have more of a federal preemption issue, 
particularly with the distributors; the McKessons, the 
Cardinals, the AmerisourceBergens, those entities, 
because those claims are often based on− you have this 
federal duty that you have to report when certain key 
things occur, you didn’t report, so now I’ve got a cause of 
action against you, and so you might run into some 
preemption issues on that. We have chosen not to file the 
distributor cases yet until we can get the discovery so we 
can point to exactly what they knew and when they knew 
it so that we can plead around and avoid any possible 
problems with preemption. But, again, it’s not really as 
much of an issue for our case, because we are not trying 
to prove you knew about this through federal regulation. 
We are saying, hey, look, you not only participated in the 
illegal drug market because you continued to ship pills to 
known diversion sources. So, it’s completely outside of 
that realm. And so, we’re a little bit different in what we 
do. But, yes, they are raising any and all defenses that 
they can to delay this as long as possible. 
 
MR. GROVES: Thank you. Ms. Herzfeld, you 
mentioned the remedies that are available for some of 
these causes of action. Can you talk about what kind of 
damages that you are hoping to obtain for the clients that 
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you represent, and are there any procedural or legal 
obstacles that you face in obtaining those damages? 
 
MS. HERZFELD: So, we are hoping to obtain 
really big damages for our clients, huge, huge, and there’s 
a lot of reasons for that, not because anybody is trying to 
get rich; right? When you look at these towns and you 
look at− Sullivan County, Tennessee, is a great example. 
I think someone in the audience said earlier that the 
towns are emptier. They are full of people that can’t get 
jobs, because nobody can pass a drug test, and that’s 
nobody’s fault; right? I mean, it’s not because you decided 
that you were going to become a drug addict and that’s 
how you wanted your world to end up. Nobody intends to 
become a drug addict. But you did have a workplace 
injury because you worked in the coal mines or you 
worked wherever it is, and your doctor gave you these 
drugs. Nobody intends to get addicted. Nobody intends to 
become a drug addict. And the consequences of that are 
just devastating, especially in a small town. We know 
that there are employers that have jobs they can’t fill 
because they cannot find sufficient people to pass a drug 
test. So, our case not only includes damages for the town, 
which I’ll talk about more specifically in a minute, but 
also claims for babies. So I think our case is the only 
casein the country, at least the last time I checked, where 
we have included claims on behalf of particular infants, 
and these are individual children whose identities are 
sealed; I know who they are, but their identities are 
sealed, and they were babies that were born dependent 
on these drugs, so their birth mothers took the drugs 
during pregnancy and at some point gave birth to these 
children who suffered enormously.  
So, I would like to talk about their damages first. 
What we know about the children that are born with 
neonatal abstinence syndrome is actually, pardon the 
pun, in its infancy. It’s not something that has been 
studied for an extraordinary amount of time, but this 
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phenomenon, neonatal abstinence syndrome and opioids, 
hasn’t been around that long. Here’s what we know: 
When these babies are born, they shake, they cry 
uncontrollably, you cannot sooth them. That is the one 
thing you will hear everyone say. They scream and 
scream and scream to the point where their volunteers 
whose only job is to cuddle the babies. They just walk and 
cuddle and rock and walk and cuddle and rock. And why 
is it? Because the children have had a constant supply of 
these highly-addictive medications in utero, and once 
they are born, it’s discontinued. Do you know how they 
treat those babies? Morphine. They have to give those 
babies morphine. In the first days of their life, they are 
given a bit and then they wean them down and they wean 
them down and they wean them down, and so they end 
up in the neonatal intensive unit and they are being 
given controlled doses of morphine to wean them down. 
So that’s the first few weeks, which is crying and shaking 
and rocking and horrible. But then what comes next? You 
have a lifetime of learning disabilities: oppositional 
defiant issues, inability to concentrate, emotional 
outbursts that they don’t understand why that is 
happening; the parents, the grandparents, foster 
parents, no one understands why this child is just not 
behaving in a way that makes sense, and what we’re 
finding, through the studies, is that most of that can be 
taken back to this exposure in utero. Babies are 
developing; there’s stuff that happens there. So, we are 
trying desperately to get damages for those babies. We 
know that they will have a lifetime of medical needs, a 
lifetime of special needs. They need early intervention. 
The educational costs, imagine the educational costs of 
taking a child with needs. We don’t quite understand 
through essentially 20 years. We don’t know what that is 
going to look like. And Tennessee has the highest number 
of babies born with neonatal abstinence syndrome due to 
opioid addiction. 
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MR. STRANCH: It’s a baby born every other day 
dependent on opioids. 
 
MS. HERZFELD: It’s so bad that the Children’s 
Hospital up there had to open up its own wing, its own 
wing with its own beds just for these babies. So, I don’t 
want to lose sight of that. Of course, we’re filing through 
District Attorneys who are seeking truth and justice and 
going to get the bad guys and drug dealers out of their 
districts; right, and that’s true and important and 
amazing, but also, it’s the babies; right? It’s the people 
who are raising the babies. It’s the families that are 
broken and destroyed by the fact that now the 
grandmother or the auntie or the cousin that’s raising 
these babies. And when you take that, and you multiply 
that not just from a one-family perspective, but from an 
entire community, the devastation is extraordinary. So 
what kind of damages are you hoping to get? Well, let’s 
see, prosecutors have to spend more time prosecuting, 
cops have to spend more time arresting, more Narcan, 
more ambulance costs, more emergency room costs, more 
overdose costs, more educational costs. Court system 
costs go up; right? Everything exponentially goes up. 
Those resources might have been used for other things, 
positive things, but instead they are all being diverted to 
deal with this completely overwhelming crisis.  
So, what are the damages? Good question. They 
are enormous. The other thing we have asked for, in 
addition to damages to fix all the stuff that’s happened in 
the past, is, we have asked for injunctive relief going 
forward, and that sounds crazy; right? How do you get 
injunctive relief on a pill epidemic, an illegal pill 
epidemic? But that’s what we want. We want the drug 
manufacturers to stop. That’s just the answer, stop, stop 
doing it. You know what you are doing, you know what 
the harms are, stop putting profits over people, stop. And 
if that means that they have to pay for remediation in 
order to make these things happen, in order to not only 
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make the communities whole for the past damages, but 
to pay for rehab beds, education, different drug courts, 
these types of things going forward to kind of help fix that 
damage, special ed students, all these things, they all 
need to pay that going forward. So, the damages are 
huge, and I think it will probably be a bit challenging to 
figure out exactly how big, because there’s a lot of zeros 
there. 
 
MR. STRANCH: One of the things you need to 
know about that, like in Hawkins County, the sheriff did 
an analysis at the jail. Eighty-eight percent of the jail 
population, which was full, was there because of pills, 
either DUI while high on pills, stealing to buy pills, 
domestic violence while high on pills. It’s all pills. It’s 88 
percent of the jail in Hawkins County. And so, we really 
can’t emphasize enough how bad this is in the 
communities. It’s easy when you’re in a city like 
Knoxville to miss exactly what’s going on in some of these 
smaller communities. 
 
MS. HERZFELD: We missed it. We didn’t know; 
right, until we knew? I mean, we didn’t know until we 
knew. It’s devastating. 
 
MR. GROVES: Professor Buck, we have heard a 
little bit about the suits against these drug 
manufacturers. Just from a broader public health 
perspective, what are the similarities in this type of 
litigation against the drug manufacturers to the 
litigation that occurred against Big Tobacco in the 1990s, 
and are there any differences? 
 
MR. BUCK: Sure. So, focused on manufacturers 
for a minute and talking federal regulations. I think 
there’s one kind of major similarity, and that is, in many 
of these claims that are the federal claims, there is a core 
to them that focuses on some kind of fraudulent 
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advertising. So the drug companies are actually 
advertising these drugs either direct to consumer or in 
doctors’ offices in some way that can be alleged to be 
fraudulent, and in that way we have a similarity with Big 
Tobacco in the 1990s. You know, they’re burying bad 
science, they’re minimizing poor results from clinical 
trials, and they may be actually misbranding these drugs 
through their misleading advertising. But beyond that, 
there are a lot of differences, and in particular there are 
three that I was able to kind of come up with in thinking. 
First, opioids have a lot of regulation around them to 
begin with. They actually are FDA approved to treat 
chronic pain, and we have been talking a lot about misuse 
of opioids and illegal use of opioids, but I think it’s 
important to also recognize that through the last 
generation of health law and policy, there’s been a lot of 
discussions about how chronic pain in this country is 
undertreated and how individuals have a stigma 
attached to them who are facing chronic pain, as well as 
the individuals who prescribe those drugs, and that’s 
complicating the regulation of these drugs in a way that 
never complicated the regulation of tobacco. Tobacco was 
not subject to FDA approval until 2009 in this country. 
Drugs that are sold in this country are approved by the 
FDA, and so we have a regulatory structure in place from 
the federal perspective that is different than tobacco in 
that regard. The second I guess you could say a way that 
these are very different is that these drugs are subject to 
a number of antifraud tools at the federal level when 
we’re talking about manufacturers. So, the most potent, 
you can talk about the False Claims Act.  
The federal government is able to go after 
manufacturers who misbrand their drugs, who advertise 
their drugs to doctors in ways that are untrue, because 
the federal government pays for these drugs through 
Medicare and Medicaid, and these programs allow the 
federal government to empower the Department of 
Justice to go after manufacturing companies who make 
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untrue statements in their advertisement. The problem, 
of course, with this way or this pathway is that there’s 
often a desire to settle these cases, particularly of course 
from the drug companies’ perspective, but also from the 
Department of Justice. There’s been a reliance on 
Corporate Integrity Agreements over the last couple of 
years that are put in place to try to govern drug 
companies’ behaviors going forward and check in every 
quarter on pricing or advertising. And I think the biggest 
challenge here is that misbranding is really profitable for 
these manufacturing companies. So if you’re a 
manufacturing company and you have gotten your drug 
approved for a narrow segment of the population, but you 
can go into a doctor’s office and allegedly talk about an 
off−label use that the FDA has not approved your drug 
for, which is the case in the Purdue case around 
Oxycontin, they were minimizing the addictive effects of 
the drugs to the doctors; that’s the allegation. There’s a 
huge market out there for which you do not have to go 
through the FDA to seek approval. You can get doctors to 
prescribe your drug off label, and often doctors will do so. 
It’s a very profitable thing, if you are a private company 
and you owe a duty to your shareholders to maximize 
profits and you see that you can open up the market by 
eight, nine, ten billion dollars and the statutory penalties 
might only amount to a two or three-billion-dollar 
settlement, that’s a calculation that many drug 
manufacturing companies make. And so, I guess the 
thing that I would say about this is that our enforcement 
and regulatory system here is not potent enough and that 
we settle too much with drug companies in this respect.   
Of course, there’s also a challenge that if you take 
a drug company to trial for one of these cases, what faces 
them, in the event of a bad verdict from their perspective, 
is exclusion from Medicare or Medicaid, and that means 
they can’t basically do any business with anybody related 
to the American healthcare system, to which they make 
the argument to the Department of Justice this is 
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something that will hurt a lot of people. Like the Pfizers 
of the world going to court and saying we do a lot of good, 
so you can’t exclude us because think about all the 
patient harm that will come. And I know I’m blowing that 
out of the perspective there, but that’s the heart of the 
argument from the pharmaceutical company. The final 
thing, the third I think big difference is going back to a 
point that I had made earlier, which is a lot of these 
drugs− and this is what makes this problem so 
complicated and much more complicated than the tobacco 
problem− is that, again, these drugs, some of them are 
indicated, some of them are legitimate. We can’t 
categorize them all in one way or the other. And we built 
the system, at least in this country, around prescription 
drugs that values professional autonomy, and it 
complicates the regulation of prescription. We trust our 
doctors and we give them a lot of authority and discretion 
to make determinations about our drugs. And so, the best 
way I think we can try to go about this problem is to go 
after the manufacturers using the tools I mentioned. I 
think those are the things that complicate the analysis 
when we’re comparing it to tobacco. 
 
MR. GROVES: Mr. Stranch, Professor Buck just 
talked a little bit about the federal government’s 
involvement from a regulatory perspective, but let’s talk 
about what the Justice Department has done just in the 
past year. In August of 2017, the Justice Department 
announced the formation of the Opioid Fraud and Abuse 
Detection Unit, which will temporarily provide financial 
resources to 12 of the 94 U.S. Attorney’s Offices for the 
purposes of prosecuting health care fraud and abuse, and 
the Eastern District of Tennessee U.S. Attorney’s Office 
was selected to participate. So how significant of a 
development is this in your mind, and in general what 
should the role of the federal government be in 
combatting this crisis? 
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MR. STRANCH: I mean, they’re putting drapes on 
a burning house. You’re not going to arrest your way out 
of this problem. It’s way too big. The time to do that was 
25 years ago. And the federal government, there’s been a 
complete failure of the regulatory system to do anything 
about this, both at the state and at the federal level. I can 
tell you, from representing District Attorney Generals, 
that they are absolutely underwater with pill problems. I 
mean, it’s the number one thing they deal with. We have 
even got one DA that we’ve talked with who says, look, if 
I dig hard enough on any case that comes into my office, 
there’s going to be pills in there somewhere, I’ve just got 
to dig deep enough to find it, and I take a little slightly 
view, I say maybe in 99 percent of the cases, but he’s 
adamant it’s a hundred percent. That’s how bad the 
problem is. So, some funding to help find opioid fraud and 
abuse and maybe shutdown a pill mill here or there, it 
will be nice, it will help, but it’s− I mean, you’re standing 
at a breaking dam and you’re sticking your finger in a 
crack. It’s going to take the full weight of the federal 
government, the state government, the court system 
through private litigation and the legislature in changing 
laws if we’re actually going to try to get ahead of this 
problem, because right now we have not even hit the crest 
of the tidal wave. It is still coming. It is still getting 
worse. Every year there’s more babies born dependent on 
opioids. Every year there is a rise in the number of deaths 
due to overdoses. And even in places where we have seen 
the overdose deaths start to level out, what we are seeing 
is a number of overdoses have continued to rise anyway, 
and what it is a reflection of is, now they have Narcan in 
the cop cars, now they have Narcan in the ambulances, 
so they can deploy immediately when something 
happens.  
We have got districts that we’re working with 
where they’re putting it in schools because kids are 
overdosing at school on opioids. So, a couple of million 
bucks from the Department of Justice to put five or six 
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people looking at pill mills is not going to change 
anything. I mean, it’s a window dressing so that someone 
can stand up and say, look, we’re doing something, but 
they are not really doing anything at all. I will speak 
briefly about Purdue for a second. They pled guilty to 
misbranding back in 2006, and they admitted to what I 
call the Holy Trinity of Lies. They said we told people that 
if you have true chronic pain, you will not become 
addicted to our pills. We told doctors and people if you 
have true chronic pain, you won’t develop a tolerance to 
our pills. And we told people if you have true chronic pain, 
you won’t go through withdrawal when the pills are 
taken away. They admitted in their criminal guilty plea 
that those statements were all false and they knew they 
were false at the time they made them, and these are 
statements that they were training their people to go out 
and detail doctors and tell them this over and over and 
over again, and it went on for over a decade before the 
federal government got involved on it. And during that 
time, Oxycontin use went from a mid-eight figure drug to 
a billion dollar drug every single year and created an 
entire generation of doctors that believe these scientific 
facts that are not facts that are in fact false, and it 
created an entire generation of addicts, and despite that 
guilty plea, despite paying $600 million that they paid as 
part of that and agreeing that they’re not going to do that 
and submitting to all these monitoring programs with 
states and the federal government where they’re 
supposed to submit, here’s the list of doctors that are 
prescribing our pills at certain levels, there’s been no 
enforcement action on that at all, and they have 
continued to do the exact same thing. At the time we filed 
our first complaint, they were still pushing OxyContin for 
use in chronic pain, for people that have a history of 
substance abuse and saying they probably would not get 
addicted or less likely to get addicted. This is on web sites 
that they run that they host with their name on them 
that are designed for doctors to answer their questions 
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about the drugs. The regulatory world failed, and they 
have done nothing about it. And having a couple more 
people in the U.S. Attorney’s Office who are focused on 
pill detection and finding street−level drug dealers, it’s 
going to do nothing. 
 
MR. GROVES: In the second half of the discussion 
I want to talk about some legislative policy proposals that 
are percolating in the Tennessee General Assembly, but 
before we get to that, Professor Buck, I’m going to throw 
the ethics question at you. Rule 1.6(c)(1) of the Tennessee 
Rules of Professional Conduct requires lawyers to review 
information relating to the representation of a client to 
the extent the lawyer reasonably believes disclosure is 
necessary to prevent reasonably certain deaths or 
substantial bodily harm. So, what are the implications of 
this rule for attorneys that are representing the 
pharmaceutical companies? 
 
MR. BUCK: Well, I think that the reasonably 
certain deaths or substantial body harm in 1.6(c)(1) 
probably is not as applicable as you might think when 
you take a look at it, because the individual that 1.6 
contemplates is identifiable, and it’s hard to make that 
causal link if you’re representing a pharmaceutical 
company. I think that the ethical question that is perhaps 
more interesting is, what if you find yourself 
representing a pharmaceutical company that wants to 
engage in some kind of activity that you think is 
fraudulent. This happens a lot in the health care world 
when I talk to people who practice, and it’s one of the 
things that keeps them up at night. If our client 
determines that they have gotten overpaid by Medicare 
or if they find that some of their scientific statements 
aren’t defensible, what is my role as the attorney?  
Tennessee’s rules are permissive in that instance, 
so you, as the attorney, have the ability to disclose, it’s 
not required, but it is available to you if you think that 
16
Tennessee Journal of Law and Policy, Vol. 13, Iss. 3 [2018], Art. 4
https://trace.tennessee.edu/tjlp/vol13/iss3/4
REGULATION, RESPONSIBILITY, AND REMEDIES 
13 TENN. J.L. & POL’Y 317 (2018) 
 
 
[333] 
you need to in order to prevent an ongoing crime or fraud. 
And withdrawal also is permissible, and so in the event 
that you might find yourself advising a client that’s 
unwilling to reconsider a course of action, the withdrawal 
would be permissive. There are cases in which 
withdrawal is required, and that is when you know that 
your client is using your services to perpetrate a crime, 
so the line between those two standards is pretty blurry, 
but usually there’s a lot of discretion given to the attorney 
to decide what he or she needs to do in that instance, but 
it is not an easy place to be in, and it happens I think 
fairly regularly, so it’s worth thinking about when you’re 
talking about the topic. 
 
MR. GROVES: Now we will make that transition 
and we’re going to talk more about legislative policy 
proposals. As many of you might know, Governor Haslam 
recently announced his Tennessee Together Plan, which 
proposes a host of legislative and regulatory efforts to 
fight this epidemic, and the plan emphasizes three 
different strategies: prevention, treatment and law 
enforcement. So, I want to spend the rest of our time 
talking about this, and then at about 2:00, 2:05 we will 
open it up to audience questions; you can be writing those 
down. So, Ms. Herzfeld, some lawmakers in the General 
Assembly have suggested that one way to prevent future 
opioid addiction is to limit the supply and dosage of opioid 
prescription such as what was mentioned earlier, 
limiting new patients to a five−day supply. Others are 
calling for prevention education in public schools. What 
is your reaction to some of these preventative policy 
proposals? 
 
MS. HERZFELD: I think they are all really good 
ideas, and they are very, very well intentioned, but I 
think as Gerald has made it clear, we are really just kind 
of nipping around the edges at this point. Legislation 
alone isn’t going to fix the problem. I like the 
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three−or−five−day limit on the ability to get those pills. 
That is something that we have noticed is a really big 
deal. The stuff that we have reviewed, I mean, just the 
sheer number of pills that are given to folks, it’s crazy. I 
mean, it’s a crazy amount, when you’re getting a 
30−daysupply and five pills a day and four refills and 
doctors don’t even worry about it; sure, you want another 
refill, no problem. I had my tonsils out a couple years ago 
and they had given me hydrocodone, I think, and of 
course I had taken it for two days. I had my tonsils out; 
right, in my 30s, and it was painful, but after the second 
day, I was like my God, get me off of this stuff, like please.  
When I went for my follow−up a week after, the 
doctor is like do you want more hydrocodone? And I’m 
like oh, my God, no. They just hand it out to you so easily. 
And, again, I don’t think they mean anything by it. I 
think they’re trying to be helpful, at least in some 
circumstances. So, limiting that and limiting who can 
prescribe I think is really another important thing. You 
have a lot of nurse practitioners− and this is not to get 
down on nurse practitioners− but you have a lot of nurse 
practitioners who don’t have sufficient supervision who 
are running things kind of on their own and you are 
seeing an extraordinary number of these pills getting into 
the system that aren’t necessary, they are not medically 
necessary, it’s too much, it’s overkill, and a lot of that is 
coming through nurse practitioners. So, there’s a lot of 
things. There needs to be accountability; what is the 
enforcement mechanism if somebody is violating. There 
needs to be monitoring. There needs to be limitations on 
all that. I don’t think it can just kind of be one thing and 
here’s a little bit of education and we’re going to take the 
pills and make it for five days. It has to be a more 
omnibus kind of gigantic regulatory scheme to even begin 
to make a dent. 
 
MR. GROVES: Mr. Stranch, I was going to ask 
you if you thought $25 million was enough to fund 
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treatment and recovery services, but I think I know your 
answer to that. 
 
MR. STRANCH: Twenty-five million bucks won’t 
even run a quality facility in one area of the state for a 
year. Again, window dressing is all it is. What you need 
to know about addiction when you’re dealing with opioids 
such as this, you actually have multiple levels of addition 
you have to break. You have to break the chemical 
dependency. For many people in Tennessee, that is 
actually broken while they are in jail, because they lose 
the opioids, they go through withdrawal in jail. 
Oftentimes they receive little to no medical care or 
therapy as part of that process. They just literally detox, 
go through the shakes, horrible diarrhea, headaches, 
nausea, throwing up in the jailcell. That’s how it 
normally goes. Once you break the chemical dependency, 
you still have a behavioral dependency that has to be 
broken as well, and your brain won’t go back to the way 
it was before you started taking opioids for 12 to 18 
months after you have broken the chemical dependency, 
and so that’s why you have so many people that relapse 
in that first year, because their brain is still not back to 
normal and they’re feeling depressed, the hormones and 
things inside your brain and the way it works and the 
receptors are not working right again. They’re still not 
back to normal, so it’s easy to slide back to the addiction, 
because that feels good at that point. And so, if you really 
wanted to do this correctly, I mean, you can look at 
programs like the Tennessee Medical Association; they 
have an assistance program for doctors that become 
addicted.  
It’s a multi-year program once you enter it, and 
you lose your medical license if you don’t complete it. 
They have an 85-percent cure rate, but it’s a multi−year 
program. You have to go inpatient depending on the level 
of your addiction. You have regular meetings with people. 
You have regular drug tests. You have therapy on a 
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regular basis, not like 12−step−type stuff, but like sit 
down and talk about what’s going on in your life, what 
are your triggers, help to identify your triggers so you can 
deal with them, and $25 million is not going to let you do 
that for a couple hundred thousand Tennesseans that are 
currently addicted right now. Twenty-five million is not 
going to let you do it for 400 or 500 Tennesseans in one 
small area, and it’s certainly not going to provide the 
aftercare once you break those addictions and you’re 
trying to re-enter society as− as my father would always 
say for me, I just want you to be a taxpayer− try to 
become a taxpayer again. There’s no support services for 
that. Twenty-five million dollars is nothing. 
 
MR. GROVES: Professor Buck, part of the 
Tennessee Together Plan also involves law enforcement, 
and so the question that I have is, how do we enforce 
criminal laws that are already on the books with respect 
to users and distributors while also not re−enforcing the 
negative stigma that is associated with addiction or 
prescribing? 
 
MR. BUCK: I think it’s a very hard question to 
answer, so I’m just going to take up a couple minutes and 
then we can go to the audience. But going back on what 
was previously said, I mean, we don’t think about this as 
a holistic problem, you think about physicians or dentists 
prescribing these drugs and you ask yourself, well, why 
would they? Well, first of all, they are seeking to treat 
some symptom that you might have, but also, they are 
incentivized to do that. We pay them to prescribe in this 
country. Medicare pays more for drugs that are more 
expensive to those doctors. They get a higher cut of the 
cost. And so, until we actually look at our own laws that 
actually create some of this problem in the first place and 
reverse them, we’re not really going to make any dent in 
the problem. In talking about the criminal aspect, I 
mean, these issues that are so interesting find 
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themselves on the line between public health and 
criminal law, and I think part of the challenge is to 
adequately calibrate the response.  
Is it a public health problem or is it a criminal law 
problem? I’m somebody who approaches these issues 
from kind of a health policy perspective, and so I’m much 
more likely to treat them at least on the addict side as a 
public health problem. It reminds me of the case where 
the students, common law students in here or others who 
recently graduated, Ferguson versus the City of 
Charleston that you might do in common law. It becomes 
a Fourth Amendment case, but in that case the issue is a 
hospital is testing the blood of pregnant women who 
comes to the hospital against their consent, and then for 
women who test positive, they are given the option of 
either entering a drug counseling program or going to 
jail. Now, if you think about that and apply a public 
health lens, that’s a terrible program, because not only 
does it penalize people who might need medical 
assistance, but it deters people who need prenatal care 
from coming to the hospital in the first place. So, the first 
thing I would say to the governor is, do no harm, don’t 
have a system in place that deters people from seeking 
help that they need. And so, in that perspective, a public 
health perspective, would say let’s put more money on 
drug rehabilitation centers, let’s expand Medicaid in this 
state, let’s provide care for people who need it who don’t 
have access to these services, but I don’t think that’s the 
total answer. I think the other part of it is, you have got 
to calibrate the penalties for those that have the ability 
to change their behavior, and that’s the manufacturers, 
it’s the drug companies, it’s the distributors, and maybe 
it’s the doctors; maybe we need to change the way we pay 
physicians in this country, and also think about what we 
can do to the regulatory mechanism. Is it really doing 
enough to deter the pharmaceutical companies in this 
country to think twice about advertising their drug in a 
way that they can alleged to be fraudulent, even if it’s the 
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case that they stand to make a lot more money if they do 
so. So, I think we need to think about it from more of a 
holistic perspective. I think you have to be really careful 
that you don’t harm providing care for people who need it 
by leaning too far toward criminality for those who are 
struggling from addiction. 
 
MR. GROVES: We will open it up to questions 
now. I believe we have a couple of microphones that are 
going to be walking around, so if you will just raise your 
hand and I’ll call on you. I think right here in the front. 
 
UNIDENTIFIED SPEAKER: Thank you. As an 
attorney, if I’m working with the DPR and I’m being 
accused of knowingly lying three times with regard to 
relevant facts, even if I’m cooperating and remorseful, I’m 
going to lose my license for some period of time at least, 
and why do the manufacturers not lose their license for 
some period of time at least when they knowingly mislead 
and fraudulently tell things like that? 
 
MR. STRANCH: Because our government is not in 
the business of shutting down big business. They cut a 
deal with them, they take some money, they let them 
move on. I’ll give you an example of how bad it is. In our 
lawsuit, we sent requests for admissions. Each one of the 
facts that they admitted in that criminal guilty plea, we 
asked them just to admit it in our lawsuit, and they 
refused. They denied each one of them, said they are not 
true facts. 
 
UNIDENTIFIED SPEAKER: I was just 
wondering, you had mentioned that there are kids 
overdosing in schools now and I was wondering are those 
primary, middle or high schools? What’s the frequency 
that you all are seeing this now and where in the state, 
which schools, what area is that happening? 
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MR. STRANCH: It’s actually happening across 
the country. It’s showing up in high schools. So, one of the 
big things that’s going on is, school boards are now 
discussing whether they want to deploy Narcan in the 
high schools, because there’s been about a dozen or more 
overdoses that have occurred in high schools where kids 
would go to school, take a couple pills to help float their 
math class and OD. It’s particularly becoming a problem 
with the introduction of fentanyl and carfentanyl, which 
is dangerously potent, and you don’t really know how 
strong it is, because they’re pressing out pills to make it 
look like something, sticking a little fentanyl in it, and 
sometimes you’re getting a dose that’s ten times what you 
think you’re getting. They had an outbreak down in 
Florida recently where I think it was 12 students 
0D’dand died where they were all taking the same pills 
that were supposed to be one strength but were actually 
about 10, 12 times that strength. And so, yeah, it’s 
happening in high schools all over the country. I know 
there’s been a couple of deaths in Ohio. There were the 
deaths in Florida. We have talked to a couple people here 
in Tennessee that are looking into it for their high schools 
as well, as to whether they ought to be deploying Narcan 
for suspected overdoses in the school. It’s a real problem. 
 
MR. GROVES: We have another question down 
here. 
 
UNIDENTIFIED SPEAKER: This might be more 
of a rhetorical statement or rhetorical question. I’m 
thinking somewhat of an analogy to what’s happened 
with the groundswell against the NRA for what 
happened I guess a week and a day ago in Florida where 
at least the kid seemed to be −− there seems to be some 
friction, some impetus to fix. So, here’s my analogy, and 
I’m not sure it works, and I’m wondering what you think 
about it. So if I’m a doctor in Sullivan County, or a 
dentist, and I’m figuring I’ve got, off the top of my head, 
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a hundred colleagues, maybe 50, and I’m going to the 
local county club once a month to meet with them just to 
−− I don’t understand how the doctors in a smaller 
community like that, why there can’t be some 
groundswell from them that would be effective in 
preventing this or something. 
 
MS. HERZFELD: I think with a lot them, there 
actually is. We have talked to an extraordinary number 
of doctors who actually have an incredible amount of 
remorse, who have unwittingly participated in this and 
not realized. We were just talking about −−Gerald and 
our other law partner, Jim, were telling the same story 
about doctors who have said I have prescribed so much 
opioids, I have given all these things, and now I’m looking 
back going, oh, my goodness, how many people did I hook, 
how many people did I harm, and they were talking about 
two different doctors and two completely difference 
conversations, which is wild; right? But it’s not. There’s 
been a million articles− you can Google it− of doctors 
sitting down and saying did I contribute to this, how did 
I do this, and how do I get out of it, because now you have 
patients coming to these doctors, and I’m talking about 
the legitimate ones, I’m not talking about the Fentanyl 
pill mills; that’s a drive−through business. It’s different. 
It’s criminal. But for legitimate doctors, I mean, they are 
now trained to ask what is your pain level; right? When I 
was growing up, nobody asked that. It was how are you 
feeling, what’s your blood pressure, looked at your heart 
rate, blah, blah, blah.  
But now it’s please rate your pain. So, we as a 
society now expect the doctors to keep us out of pain, and 
if you go to your doctor and say I’m in pain and I have got 
this root canal, you haven’t given me enough medication, 
you’re mad at your doctor for keeping you in pain, and 
the truth of the matter is, he’s actually good; right? I 
mean, not all the time and not an extraordinary amount, 
but it is natural. There is a thing about pain. Sometimes 
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you’re going to be in pain. That root canal is going to hurt. 
So, I think that friction between the doctors and the 
patients of I’m expecting you to make me feel better and 
the doctor doesn’t want to give you something but yet 
needs to give you a little something and there’s a dance 
there. There have been some extraordinary things 
written that you can find online where doctors talk about 
that struggle. 
 
MR. STRANCH: By the way, the whole focus on 
pain and how we should never have pain, there’s all these 
groups, Americans Against Pain, the American Society 
for the Prevention of Unnecessary Pain, I mean, they are 
all front organizations that have been funded by the 
opioid manufacturers, and that’s what started this fifth 
vital sign of your pain, because they want to be able to −− 
they have something that they can justify, but it’s 
completely subjective. My grandmother, for example, 
every time she goes to the doctor −−she’s on her fifth bout 
with cancer −− doctor says what’s your pain on a level of 
one to ten. It’s ten. Every time it’s ten. The doctor finally 
says to her, well, it’s always ten. She says, well, yeah, 
either it hurts or it doesn’t. That’s what it is. That’s the 
way she views it. And so, what this pain thing is, it gave 
the doctors the ability to write down in the chart pain of 
eight, oxycodone and give support for it, when it’s just a 
completely subjective measure. There’s nothing objective 
about it. It’s not like your blood pressure or your white 
blood cell count or your temperature. It’s just a complete 
subjective thing that is used to justify prescribing pills. 
And they use these front groups to go in and train and to 
talk to doctors that people should not be feeling pain on 
a day−to−day basis. You should not ever feel pain, pain 
is bad. Well, that was an actual sea change in the way 
doctors view things.  
I blew my knee out playing rugby in the ’90s and 
had to have a knee surgery. When the surgery was done, 
the doctor said to me afterwards, look, I’m going to give 
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you this five-day prescription for pills, but I only want 
you to take them when the pain gets to be too bad. The 
pain is supposed to be your guide. It tells you what you 
can and can’t do with your knee. If it hurts, stop doing 
what you’re doing, because you’re going to over-extend 
and reinjure yourself. That’s what the purpose of the pain 
is. It’s a warning sign to you to don’t do that. And they 
have completely changed that. And the doctor told me you 
should probably only be taking these pills at night, 
because you’re going to be worn out, your knee is going to 
be hurting and it will help you fall asleep. That was it. A 
friend had a very similar surgery last year. He got a 30-
day supply of Oxycontin and the doctor said, "And if you 
feel any pain at all, you call me, and I’ll get you something 
stronger." That’s the change, and it’s this emphasis on 
pain that is not created through the medical community 
by doctors doing largescale studies, blind studies, double 
blind studies, observational studies, longitudinal studies, 
it was created by a bunch of front groups that the opioid 
manufacturers supported, because that’s how they can 
push their pills. 
 
UNIDENTIFIED SPEAKER: The first ten years 
after law school, I did plaintiffs’ asbestos work and so I 
know what’s in front of you and I wish you well. I’m 
interested in causation and damages. Addicted children, 
they don’t all have these horrible effects later in life. Now, 
I’m in family law and I know that. So the test that we 
were stuck with is, if you’re going to say− we were faced 
with this: Okay, yeah, this guy has had all this asbestos 
exposure, he has a much, much higher risk of contracting 
cancer later on, but you have got to prove it’s more likely 
than not that this guy is going to have cancer, so how are 
you going to, A, prove that this baby is going to have 
learning disabilities and obstructive disorder eight, nine, 
ten years from now and there are kids that have learning 
disabilities and obstructive disorder who never were 
exposed to opioids? So, you have got to get over that too, 
26
Tennessee Journal of Law and Policy, Vol. 13, Iss. 3 [2018], Art. 4
https://trace.tennessee.edu/tjlp/vol13/iss3/4
REGULATION, RESPONSIBILITY, AND REMEDIES 
13 TENN. J.L. & POL’Y 317 (2018) 
 
 
[343] 
that it’s this and he wouldn’t have just already had it, and 
I can’t imagine how you’re going to do that. So how are 
you going to do that? 
 
MR. STRANCH: For starters, the Drug Dealer 
Liability Act has a specific section that deals with 
assigning claims to babies that are exposed in utero. So, 
they have a specific test already for what you can do, and 
we know for the kids that we filed, they already have 
those problems now. They already have impulse control 
problems now. 
 
UNIDENTIFIED SPEAKER: How old are they? 
 
MR. STRANCH: They range in ages. Most of them 
are close to school age or in school. 
 
UNIDENTIFIED SPEAKER: Some of them will 
graduate from college before you’re through. 
 
MR. STRANCH: More than likely, more than 
likely. But one of the things that what we believe the 
current state of medicine to be on this is, look, if you’re 
exposed to significant amounts of opioids in utero, you’re 
going to have impulse control problems later in life, 
period, full stop, that’s going to happen. The question 
becomes, are you able to deal with it, control it or not, 
which is kind of ironic for someone with impulse control 
problems, but the way it works is, you have to do early 
childhood intervention and you have to work with the 
children from day one and you have to provide them with 
a stable environment so that they cannot have external 
stressors. One of the problems of the opioid epidemic is, 
of these babies that are born with NAS, like 25 percent of 
them end up in foster care within a year. Many of them 
end up bouncing in and out of foster care.  
So, they don’t have a stable environment to start 
with, which only causes to exacerbate the impulse control 
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problems. Now, if a kid gets adopted straight out of 
coming out of the NICU, goes to a stable, loving family 
and they take care of him and they provide all of the early 
childhood intervention, you may see a child that is going 
to graduate and, as my dad said, become a taxpayer. 
Greatest thing you could ever want for your kid is to 
become a taxpayer. But that doesn’t mean that there’s 
not going to be problems and struggles and the 
behavioral therapy and other stuff that’s going to have to 
be done along the way. We also know from another child 
we represented that it can be much more than just 
impulse control problems. It can literally be a question of 
will this child ever be able to be a functioning member of 
society without having to have an adult doing things for 
them and overseeing them. 
 
UNIDENTIFIED SPEAKER: The corporate boys 
are going to say prove that this kid doesn’t need $1,000 
worth of treatment rather than the$500,000 worth of 
treatment that you say he needs ten, 15 years from now. 
 
MR. STRANCH: We’re still struggling to get them 
to admit they’re selling opioids. They’re not admitting 
anything. But we’re going to have our experts that are 
going to go through and that are going to talk about 
what’s facing these kids, what’s going to happen, what 
money is going to have to be spent on them, the problems 
they’re going to have, and they’re going to have their 
experts, like in all cases where you have medical experts, 
who are going to say this kid was never harmed, and if 
there was any harm, it was because the dad had bad 
genetics or the mom had bad genetics and they all 
preexisted and had nothing to do with this, and by the 
way, would you like some opioids?  
I mean, that’s what they’re going to do. And I just 
think our experts are going to be more believable than 
theirs, because we’re going to be putting them in front of 
a jury that is going to be living in a community where 
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they’re seeing this on a day−to−day basis, where they’re 
seeing the disruption in the classroom through their kids 
and their neighbors’ kids. Our first hearing that we went 
to in our case, there was three divorces on the docket, and 
two of them was because the spouse ran off because she 
was addicted to pills. These communities know this, and 
they are not going to be very impressed with a medical 
doctor that comes in and says there’s no long−term harm 
damage from shooting up opioids during pregnancy and 
that these kids are not going to have any problems, and 
if they do, it’s because they didn’t have a stable home life 
beforehand and they’ve got bad genetics. 
 
UNIDENTIFIED SPEAKER: Baby Doe is a very 
sympathetic plaintiff. 
 
MR. GROVES: That’s about all the time that we 
have for this panel of discussion. Join me in thanking our 
panelists for joining us. 
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